Politics ❯ Healthcare Policy

Drug Pricing

Government Regulations US Government Senate Hearings US Senate Public Health High-cost Drugs Political Pressure Equity Across Developed Countries Consumer Access U.S. Politics Pharmaceutical Companies Inflation Reduction Act US Administration Pharmaceutical Industry Regulatory Issues Pharmaceutical Regulations Eli Lilly IVF Treatments Medicare Regulatory Environment Government Involvement Public Messaging Bernie Sanders Provincial Regulations NHS Funding

Oz Defends Trump’s Drug-Price Math on NBC as Fact-Checks Reject Claims of Cuts Over 100 Percent

Independent reviews say percentage reductions cannot exceed 100 percent under standard arithmetic, with the cited $242-to-$10 example equaling about 96 percent.

FDA Names First 9 Drugs for ‘National Priority’ Fast-Track Reviews, Targeting 1–2-Month Decisions

Eli Lilly Raises 2025 Outlook as Tirzepatide Sales Soar, Orforglipron Misses Marks